Efficacy and Safety of Endovascular Therapy for Aortoiliac TASC D Lesions

Kenji Suzuki1, Yukiko Mizutani2, Yoshimitsu Soga3

  • 1Department of cardiology, Saiseikai Central Hospital, Minato-ku, Tokyo, Japan k-y.suzuki@nifty.com.

Angiology
|March 17, 2016
PubMed

Insights

Endovascular therapy for complex aortoiliac occlusive disease, including TASC D lesions, shows lower procedural success but similar long-term patency and major adverse events compared to TASC A-C lesions.

Area of Science:

  • Vascular Surgery
  • Endovascular Interventions
  • Peripheral Artery Disease

Background:

  • Endovascular therapy is increasingly effective for aortoiliac (AI) occlusive disease.
  • Application to TASC D lesions remains less understood and applied.

Purpose of the Study:

  • To compare outcomes of endovascular therapy for TASC D aortoiliac lesions versus TASC A-C lesions.
  • To identify predictors of major adverse cardiovascular and limb events (MACLE) in TASC D patients.

Main Methods:

  • Retrospective analysis of 2096 patients (2601 limbs) with AI occlusive disease.
  • Lesions categorized as TASC D (395) or TASC A-C (2206).
  • Comparison of baseline data, procedural success, complications, and 5-year follow-up results.

Main Results:

  • Lower procedural success (91.6% vs 99.3%) and higher complication rates (11.1% vs 5.2%) in the TASC D group.
  • No significant difference in 5-year primary patency (77.9% vs 77.1%) or MACLE (30.5% vs 33.4%) between groups.
  • Complications and critical limb ischemia independently predicted MACLE in TASC D patients.

Conclusions:

  • Endovascular therapy for TASC D AI lesions has lower procedural success and higher complication rates.
  • Despite initial challenges, long-term outcomes regarding patency and MACLE are comparable to less complex lesions.
  • Managing complications is crucial for improving MACLE outcomes in TASC D patients.
Abstract